Economic considerations in technology assessment: the case of genetic disease.
This paper describes economic issues pertinent to health care technology assessment. Of interest are the allocation of resources between health and other sectors of the economy, between alternative services within the health sectors, and the costs of producing the services that are selected. These issues are discussed and then illustrated by reference to a specific area of health care technology: screening for and intervention against genetic diseases. It is concluded that investments in screening programs for Tay Sachs disease and Down Syndrome are allocatively efficient. Indications are that such investments are also efficient for interventions against Neural Tube Defects; however, there are complex ethical issues involved. There are many genetic diseases for which screening tests have yet to be developed. As such tests become available, each will have to be evaluated on its own merits relative to alternative health sector investments.
D003362:Cost-Benefit Analysis; D003625:Data Collection; D004314:Down Syndrome / Q000175:diagnosis / Q000517:prevention & control; D004526:Efficiency; D005820:Genetic Testing / Q000191:economics*; D006295:Health Resources / Q000600:supply & distribution*; D006801:Humans; D013661:Tay-Sachs Disease / Q000175:diagnosis / Q000517:prevention & control; D013673:Technology Assessment, Biomedical / Q000191:economics*; D014481:United States